Granulocyte colony-stimulating factor (G-CSF)

DRUG19 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), OHSU Knight Cancer Institute, Genzyme, a Sanofi Company, Eli Lilly and Company, Washington University School of Medicine

Conditions

Acute Lymphocytic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)Atherosclerosis, CoronaryAutologous TransplantationBiphenotypic/Undifferentiated LeukemiaBurkitt Lymphoma

Phase 1

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

CompletedNCT00245037

OHSU Knight Cancer InstituteChronic Myeloproliferative Disorders, Leukemia, Lymphoma +4

Start: 2005-06-30End: 2015-08-31Updated: 2017-09-27

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

CompletedNCT01161550

Washington University School of MedicineLeukemia, Myeloid, Acute

Start: 2010-11-30End: 2012-08-31Updated: 2013-07-23

Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

CompletedNCT03471611

Mayo ClinicAtherosclerosis, Coronary

Start: 2018-06-15End: 2020-10-02Updated: 2022-02-07

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

TerminatedNCT04240002

Astellas Pharma Global Development, Inc.Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)

Start: 2020-09-04End: 2025-03-17Updated: 2026-01-05

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

CompletedNCT04584112

Hoffmann-La RocheTriple-Negative Breast Cancer

Start: 2020-09-28End: 2023-03-08Updated: 2023-03-15

Phase 2

G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

CompletedNCT00082329

National Heart, Lung, and Blood Institute (NHLBI)Healthy

Start: 2004-06-18End: 2012-10-25Updated: 2021-07-22

A Study for Participants With Small-Cell Lung Cancer

CompletedNCT01025284

Eli Lilly and CompanySmall Cell Lung Cancer

Start: 2009-12-31End: 2012-07-31Updated: 2019-09-17

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

WithdrawnNCT01750866

Case Comprehensive Cancer CenterCastrate-resistant Metastatic Prostate Cancer

Start: 2013-02-28End: 2013-10-31Updated: 2013-10-16

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

CompletedNCT02268695

Groupe Oncologie Radiotherapie Tete et CouHead and Neck Squamous Cell Carcinoma

Start: 2014-10-10End: 2021-12-31Updated: 2022-08-23

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

CompletedNCT02703779

Siddhartha GangulyMultiple Myeloma

Start: 2016-03-31End: 2020-04-08Updated: 2021-06-18

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

TerminatedNCT03042780

H. Lee Moffitt Cancer Center and Research InstituteGastro-enteropancreatic Neuroendocrine Tumor, Islet Cell Carcinoma, Neuroendocrine Carcinomas of Pancreas +1

Start: 2017-02-01End: 2018-09-07Updated: 2020-11-27

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active, not recruitingNCT03674411

Masonic Cancer Center, University of MinnesotaAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Biphenotypic/Undifferentiated Leukemia +8

Start: 2019-01-02End: 2026-12-01Updated: 2026-01-06

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

RecruitingNCT05139017

Merck Sharp & Dohme LLCDiffuse Large B-Cell Lymphoma, DLBCL

Start: 2022-01-14End: 2027-09-24Target: 290Updated: 2026-03-27

Phase 3

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

Assistance Publique - Hôpitaux de ParisPhiladelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia

Start: 2016-04-30End: 2025-12-31Target: 265Updated: 2019-10-21

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

CompletedNCT02961257

Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieProstate Cancer Metastatic

Start: 2017-05-05End: 2021-12-02Updated: 2022-05-12

Phase 4

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

RecruitingNCT05753618

Ottawa Hospital Research InstituteEarly-stage Breast Cancer

Start: 2023-04-17End: 2026-10-01Target: 242Updated: 2026-02-09

Unknown Phase

Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).

CompletedNCT00741325

Genzyme, a Sanofi CompanyAutologous Transplantation, Non-Hodgkin's Lymphoma

Start: 2006-06-30End: 2011-11-30Updated: 2014-02-11

Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).

CompletedNCT00741780

Genzyme, a Sanofi CompanyAutologous Transplantation, Multiple Myeloma

Start: 2006-06-30End: 2011-07-31Updated: 2015-03-24

G-CSF-Induced Bone Pain and Supportive Care Approaches

CompletedNCT07192770

Ankara Etlik City HospitalChemotherapy-induced Neutropenia, Solid Tumors

Start: 2025-09-27End: 2026-02-19Updated: 2026-02-20

Related Papers

Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.

2025-11-25

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003

Blood2025-11-03

Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

2025-08-21

WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma.

Journal of Clinical Oncology2025-05-281 citations

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

CPT Pharmacometrics & Systems Pharmacology2024-12-252 citations

Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial.

2024-08-13

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood2024-03-0723 citations

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer

JAMA Oncology2023-10-2616 citations

Leukocyte subtypes and myeloid derived suppressor cells as prognostic markers in metastatic castration resistant prostate cancer treated with cabazitaxel: A satellite study of the CABASTY phase III trial.

Journal of Clinical Oncology2023-02-20

Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma.

Journal of Clinical Oncology2022-06-017 citations

IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Arteries

Circulation Research2021-12-2044 citations

A Phase 1, Dose-Escalation Study of Gilteritinib Combined with Chemotherapy in Patients Aged 6 Months to &lt;21 Years with FLT3 Internal Tandem Duplication-Positive Relapsed or Refractory AML

Blood2021-11-05

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.

2021-03-05134 citations

Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review.

2020-12-026 citations

TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Journal of Clinical Oncology2020-05-2024 citations

Mgta-456, a Cell Therapy Utilizing Expansion of CD34+ Hematopoietic Stem Cells (HSC), Improves HLA Matching for Adult Recipients, Promotes Faster Hematopoietic Recovery and Enables Uniform Engraftment with Less Acute Graft-Vs-Host Disease (GVHD)

Biology of Blood and Marrow Transplantation2020-01-23

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Blood2019-11-134 citations

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Journal of Clinical Oncology2019-05-2082 citations

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report

Biology of Blood and Marrow Transplantation2018-02-0249 citations

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma.

Journal of Clinical Oncology2015-05-2040 citations